New FDA Draft Guidance: Elevating Safety, Transparency & Testing for Menstrual Products

Introduction

In October 2025, the FDA published a draft guidance titled Menstrual Products – Performance Testing and Labeling Recommendations (Draft Guidance for Industry and FDA Staff). U.S. Food and Drug Administration
This guidance provides non-binding recommendations for manufacturers of menstrual products (tampons, pads, menstrual cups) regarding performance testing, specification, materials/disclosure, and labeling. U.S. Food and Drug Administration+1
Once finalized, it will supersede the prior guidance “Menstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s)” (July 2005). U.S. Food and Drug Administration
Although labelled Draft – Not for Implementation, it offers insight into the FDA’s current thinking and forthcoming expectations. U.S. Food and Drug Administration

Background & Rationale

The document highlights some key drivers for its publication:

• The FY 2022 and 2023 U.S. House Appropriations Committee Reports requested the FDA update its 2005 tampon/pad guidance, with specific attention to ingredients/materials and transparency. U.S. Food and Drug Administration+1
• Growing public concern about materials used in menstrual products, including a 2024 study that found metals in tampons. Although that study did not allow risk estimation of exposure, the FDA conducted an independent systematic literature review. U.S. Food and Drug Administration
• Expansion of scope: this draft now includes menstrual cups (which were previously not covered under the older guidance). U.S. Food and Drug Administration
• Regulatory updates: e.g., the final rule to amend the Quality System Regulation (21 CFR Part 820) aligning with ISO 13485 will take effect February 2 2026; the guidance notes such upcoming changes. U.S. Food and Drug Administration

In short: manufacturers of menstrual products must prepare for more rigorous documentation, enhanced transparency (e.g., ingredients disclosure), and more detailed performance testing and labeling as the FDA raises its standards.

Scope of the Guidance

The guidance applies to menstrual products defined as tampons, pads and menstrual cups used to absorb or collect menstrual fluid or other vaginal discharge. U.S. Food and Drug Administration
Specifically it covers devices regulated under classification regulations 21 CFR 884.5425, 884.5435, 884.5460, 884.5470 and 884.5400 (with corresponding product codes) as listed in Table 1 of the document. U.S. Food and Drug Administration
It is designed to cover both devices subject to pre-market notification (510(k)) and those exempt (under 21 CFR 884.9 limitations). U.S. Food and Drug Administration

Key Elements of the Guidance

Here are the major areas addressed by the document:

Device Description & Predicate Comparison

• For devices subject to 510(k), manufacturers must compare their device to a legally marketed predicate device and demonstrate substantial equivalence. U.S. Food and Drug Administration
• The “Device Description” section stipulates that manufacturers provide engineering drawings, dimensions, component materials, etc. (for tampons, pads, menstrual cups). U.S. Food and Drug Administration
• For example: for tampons, include drawings of the pledget, overwrap, removal string, applicator (if any), both compressed and uncompressed. U.S. Food and Drug Administration
• For menstrual cups, include specification of material, dimensions, volume, coating, and how insertion is intended. U.S. Food and Drug Administration
• Component materials must be identified in terms of chemical identity and quantity, including additives/finishing agents, colorants, fragrances/deodorizers. U.S. Food and Drug Administration

Performance Testing Recommendations

One of the most substantive sections. The guidance recommends that manufacturers conduct testing to support safety, performance, and accurate labeling. Key elements include:

Biocompatibility

• Because menstrual products contact mucosal membranes repeatedly over a lifetime (even if each use is <24h, cumulative exposure matters) the guidance recommends following standards like ISO 10993 for cytotoxicity, sensitization, irritation, systemic toxicity, etc. U.S. Food and Drug Administration
• If a material has an established safety profile, less testing may suffice. But for novel materials/fibres, the full set of tests is recommended. U.S. Food and Drug Administration

Microbiology Assessment

• For tampons, the guidance emphasises testing for potential promotion of Staphylococcus aureus growth, production of TSST-1 toxin (Toxic Shock Syndrome Toxin-1), and alteration of normal vaginal microflora. U.S. Food and Drug Administration
• The guidance offers specific test methods (e.g., Tampon Sac, Syringe method, Shake Flask method) for TSST-1 testing. U.S. Food and Drug Administration
• Also, in vitro testing of vaginal microflora (Lactobacillus acidophilus, Staph aureus, Gardnerella vaginalis, E. coli, Pseudomonas aeruginosa, Candida albicans) is recommended to show the device does not significantly alter the microbial community. U.S. Food and Drug Administration

Non-Clinical Bench Testing

• For example, for tampons: absorbency specification (grams), weight of pledget, removal string properties, applicator design, etc. U.S. Food and Drug Administration
• For menstrual cups: device volume (how much fluid can it hold for the stated duration), and fluid handling characteristics. U.S. Food and Drug Administration

Clinical Performance Testing

• The guidance suggests that for certain devices, clinical use studies may be needed (especially when novel materials/designs are employed). While the document gives more detail, the key principle is that performance in real‐use settings must be demonstrated where risk warrants. U.S. Food and Drug Administration

Labeling Recommendations

The guidance provides detailed recommendations on labeling for each device type (tampons; pads & menstrual cups). Some highlights:

For Tampons

• Indications for Use: clearly state what the tampon is intended for (menstrual fluid, other vaginal discharge). U.S. Food and Drug Administration
• Device Description: materials, absorbency range (grams) as per 21 CFR 801.430(e)(1) for tampons, removal string, applicator (if any) etc. U.S. Food and Drug Administration
• Warnings: including but not limited to TSS risk, instructions for safe use, changes between tampon brands, frequency of change, handling, disposal. U.S. Food and Drug Administration
• Directions for Use: comfortable insertion, removal, disposal, hygiene considerations. U.S. Food and Drug Administration

For Pads & Menstrual Cups

• Indications: similarly defined. U.S. Food and Drug Administration
• Device Description: materials, volume (cups), absorbency (pads) though absorbency range as regulated for tampons does not apply to pads. U.S. Food and Drug Administration
• Warnings and Additional Considerations: for cups especially regarding insertion/removal, cleaning (if reusable), hygiene risks, disposal or reuse instructions. U.S. Food and Drug Administration
• Notably: ingredient disclosure — outer package labels must list ingredients, including fragrances/deodorizers. U.S. Food and Drug Administration

Modifications and Change Control

The draft guidance addresses situations where a marketed menstrual product undergoes modification (design, materials, intended use). Manufacturers are advised to analyse whether such changes necessitate a new submission under 510(k) or other regulatory oversight. U.S. Food and Drug Administration

Implications and Strategic Considerations for Industry

For manufacturers of menstrual products (or those planning to enter this market), this guidance signals several strategic imperatives:

• Material transparency & traceability: Manufacturers need to document component materials, additives, finishing agents, and ensure they are supported by established safety profiles or perform new testing.
• Robust testing programmes: Especially for novel materials or designs, planning for biocompatibility, microbiological, bench and possibly clinical testing is prudent.
• Labeling alignment: Packaging/labeling must reflect device specifics (absorbency, volume, materials, directions, warnings). Ingredient disclosures (including fragrance/deodorant) will be expected.
• Quality system readiness: With the upcoming alignment of QSR with ISO 13485 (effective February 2 2026) and the FDA’s mention in the guidance, manufacturers must ensure their QMS is ready for heightened scrutiny. U.S. Food and Drug Administration
• Market entry / regulatory submissions: For those submitting new 510(k)s or modifications, using this guidance as a roadmap will help anticipate FDA expectations, reduce back‐and‐forth, and improve submission quality.
• Risk management and novel design diligence: For innovative menstrual cups or pads (e.g., reusable/recyclable fabrics, smart sensors, novel fibres) the regulatory burden may increase—planning early for supporting data is critical.
• Global alignment opportunity: Although this guidance is US‐centric, manufacturers exporting to or from India (or other markets) may anticipate similar regulatory trends globally (increased transparency, material safety, microbiology focus).

What’s New (Compared to Previous Guidance)

• Inclusion of menstrual cups: The older 2005 guidance did not cover menstrual cups.
• Ingredient disclosures on outer packaging (including fragrances/deodorants) — greater transparency demanded.
• Specific microbiological testing recommendations addressing TSS risk and vaginal microflora changes.
• Detailed bench testing criteria for newer products (absorbency, volume, dimensions) including reusable pads or cups.
• Consideration of contaminants (e.g., metals in tampons) and manufacturer responsibilities to evaluate such risks.
• Alignment with upcoming regulatory changes (e.g., QS regulation aligning with ISO 13485).

Challenges & Considerations for Indian Manufacturers / Market

Given your context (pharmaceutical regulatory consulting in India, medical devices / products), here are some tailored thoughts:

• Indian manufacturers exporting menstrual products to the US or global markets should proactively align with this FDA draft guidance—for example by auditing material suppliers, validating biocompatibility and microbiological testing, verifying labeling meets ingredient disclosure requirements.
• Messaging around materials and transparency can also be leveraged as a marketing advantage in India (where consumer awareness around menstrual products is growing). Even if FDA regulation doesn’t directly apply in India, aligning internationally can enhance trust.
• Ensure your regulatory strategy anticipates shelf-labeling changes: if a product is intended for US market, its packaging must comply; if same packaging is used in India, consider whether local regulatory authorities might require ingredient disclosures or similar transparency.
• Consider collaborating with testing labs: biocompatibility (ISO 10993 series) and microbiological testing (TSST-1, S. aureus growth) may require specialized facilities—build those capabilities or partnerships.
• For reusable pads/cups: sustainability is a growing trend—regulatory clarity from FDA may indirectly influence Indian market expectations; highlight that your product performs per higher standard testing.
• For your regulatory affairs consultancy: you can offer a “readiness assessment” service for menstrual product manufacturers (material traceability, performance testing plans, labeling audits aligned with FDA draft guidance) — this could be a value add.

Summary & Takeaways

The FDA’s draft guidance on menstrual products signals a modernised regulatory expectation: more transparency, stronger evidence of safety and performance, and clearer labeling. For menstrual product manufacturers (tampons, pads, cups), it means preparing for elevated scrutiny around materials, microbiological safety, bench/clinical testing and packaging disclosures. Even though it is draft (non-binding), industry best practice suggests aligning early—both for the US market and for global credibility. For makers and regulators in India, there is a strategic opportunity: positioning products to global standards can differentiate and open markets.